SCHEMBL3489836

SCHEMBL3489836

CN1C(=O)N(Cc2ccccc2)c2cc(Cl)cc(Cl)c2S1(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.43
TP53 P04637 2/20 0.42
ELANE P08246 2/20 0.41
F2 P00734 1/20 0.41
PLG P00747 1/20 0.41
CTSG P08311 1/20 0.41
CMA1 P23946 1/20 0.41
CTRC Q99895 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ALDH2 P05091 1/20 0.39
ALDH3A1 P30838 1/20 0.39
LMNA P02545 2/20 0.39
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489133 0.86 F2 (0.42) MAPTTP53ELANEF2PLG
SCHEMBL3489072 0.85 MAPT (0.43) MAPTTP53ELANEF2PLG
SCHEMBL3490252 0.85 MAPT (0.44) MAPTTP53ELANEF2PLG
SCHEMBL3489592 0.84 MAPT (0.49) MAPTTP53ALDH1A1LMNAKMT2A
SCHEMBL3490284 0.84 CA12 (0.40) MAPTTP53ELANEF2PLG
SCHEMBL3489510 0.84 MAPT (0.51) MAPTTP53ELANEF2PLG
SCHEMBL3490463 0.83 MAPT (0.41) MAPTTP53ELANEF2PLG
SCHEMBL3489294 0.82 CA12 (0.43) MAPTTP53ELANEF2PLG
SCHEMBL3490594 0.82 MAPT (0.47) MAPTTP53ELANEF2PLG
SCHEMBL3488509 0.82 MAPT (0.40) MAPTTP53ELANEF2PLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D MAPT 2158/4885TP53 4577/4885ELANE 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.